For centuries, pharmaceuticals were derived from plants. Andrew Huberman, quoting Dr. Abud Bakri, reframes the peptide revolution as a new paradigm: 'mining the body' for medicine. Compounds like GLP-1 are naturally present, but when synthesized at high concentrations, they become powerful therapeutic agents.

The debate isn't about peptides replacing antibodies but about combining them. The future lies in hybrid therapeutics, such as grafting peptides into antibody CDRs or creating fusions that use a peptide for optimal target binding and an antibody scaffold for effector functions, half-life extension, and stability.

The company positions its peptide platform as the ideal middle ground in drug development. They aim to create medicines that are functionally like highly selective, less toxic large biologics (e.g., antibodies) but are structurally designed for the convenience of an oral pill, combining the best attributes of both major drug classes.

Martin Shkreli claims that from a pharmaceutical development perspective, peptides are often avoided. They possess inherent weaknesses, being more complex than small molecules but less effective than large molecules like antibodies. This makes their recent popularity in biohacking circles ironic to industry insiders.

The dominance of peptides for GLP-1 therapeutics isn't a failure of antibodies but a success for picking the right tool. Peptides have a natural advantage when the therapeutic strategy involves engineering a natural ligand, making them a better starting point for certain targets like GPCRs.

The critique of the peptide trend often misses that users aren't taking unknown chemicals. Many use compounds like Retatrutide, which is already in Phase 3 clinical trials by Eli Lilly. They are essentially front-running the FDA approval process for drugs that already have substantial clinical backing.

The FDA defines a peptide as an amino acid chain of 40 or less. Blockbuster drugs like Ozempic and Mounjaro are all exactly 39 amino acids long. This perfect fit suggests potential regulatory shaping or clever drug design to fit an advantageous classification.

Peptides are clinically categorized by whether they have identified receptors. Compounds like GLP-1s have known receptors, leading to strong, predictable effects. Others, like BPC-157, lack a clear target, resulting in more diffuse, less understood mechanisms of action.

Using the peptide Insulin-like Growth Factor (IGF) directly provides the therapeutic benefits people seek from growth hormone (HGH). This approach has a better safety profile because it bypasses the HGH-to-IGF conversion process, thus avoiding the suppression of the body's natural growth hormone levels.